Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g., clarithromycin, erythromycin), diltiazem, and grapefruit juice can increase the plasma concentrations of the estrogen or the progestin or both.
Source: FDA drug label - drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g., clarithromycin, erythromycin), diltiazem, and grapefruit juice can increase the plasma concentrations of the estrogen or the progestin or both.
Source: FDA drug label - drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g., clarithromycin, erythromycin), diltiazem, and grapefruit juice can increase the plasma concentrations of the estrogen or the progestin or both.
Source: FDA drug label - drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g., clarithromycin, erythromycin), diltiazem, and grapefruit juice can increase the plasma concentrations of the estrogen or the progestin or both.
Source: FDA drug label - drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g., clarithromycin, erythromycin), diltiazem, and grapefruit juice can increase the plasma concentrations of the estrogen or the progestin or both. In a clinical drug-drug interaction study conducted in premenopausal women, once daily co-administration of DRSP 3 mg/EE 0.02 mg containing tablets with strong CYP3A4 inhibitor, ketoconazole 200 mg twice daily for 10 days resulted in a moderate increase of DRSP systemic exposure.
Source: FDA drug label - drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
COCs Increasing the Plasma Concentrations of CYP450 Enzymes: In clinical studies, administration of a hormonal contraceptive containing EE did not lead to any increase or only to a weak increase in plasma concentrations of CYP3A4 substrates (e.g., midazolam) while plasma concentrations of CYP2C19 substrates (e.g., omeprazole and voriconazole) and CYP1A2 substrates (e.g., theophylline and tizanidine) can have a weak or moderate increase.
Source: FDA drug label - drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
COCs Increasing the Plasma Concentrations of CYP450 Enzymes: In clinical studies, administration of a hormonal contraceptive containing EE did not lead to any increase or only to a weak increase in plasma concentrations of CYP3A4 substrates (e.g., midazolam) while plasma concentrations of CYP2C19 substrates (e.g., omeprazole and voriconazole) and CYP1A2 substrates (e.g., theophylline and tizanidine) can have a weak or moderate increase.
Source: FDA drug label - drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g., clarithromycin, erythromycin), diltiazem, and grapefruit juice can increase the plasma concentrations of the estrogen or the progestin or both. COCs Increasing the Plasma Concentrations of CYP450 Enzymes: In clinical studies, administration of a hormonal contraceptive containing EE did not lead to any increase or only to a weak increase in plasma concentrations of CYP3A4 substrates (e.g., midazolam) while plasma concentrations of CYP2C19 substrates (e.g., omeprazole and voriconazole) and CYP1A2 substrates (e.g., theophylline and tizanidine) can have a weak or moderate increase.
Source: FDA drug label - drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
DRSP causes an increase in plasma renin activity and plasma aldosterone induced by its mild anti-mineralocorticoid activity.
Source: FDA drug label - drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
Substances increasing the plasma concentrations of COCs: Co-administration of atorvastatin and certain COCs containing EE increase AUC values for EE by approximately 20%.
Source: FDA drug label - drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
7.3 Concomitant Use with HCV Combination Therapy – Liver Enzyme Elevation Do not co-administer Beyaz with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations [see Warnings and Precautions ( 5.5 )] .
Source: FDA drug label - drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
7.3 Concomitant Use with HCV Combination Therapy – Liver Enzyme Elevation Do not co-administer Beyaz with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations [see Warnings and Precautions ( 5.5 )] .
Source: FDA drug label - drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
7.3 Concomitant Use with HCV Combination Therapy – Liver Enzyme Elevation Do not co-administer Beyaz with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations [see Warnings and Precautions ( 5.5 )] .
Source: FDA drug label - drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
7.3 Concomitant Use with HCV Combination Therapy – Liver Enzyme Elevation Do not co-administer Beyaz with HCV drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations [see Warnings and Precautions ( 5.5 )] .
Source: FDA drug label - drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium